Androgens and androgen receptor signaling in prostate tumorigenesis

被引：130

作者：

Zhou, Ye ^{[1
]}

Bolton, Eric C. ^{[2
]}

Jones, Jeremy O. ^{[1
]}

机构：

[1] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Pharmacol, Duarte, CA 91010 USA

[2] Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA

来源：

JOURNAL OF MOLECULAR ENDOCRINOLOGY | 2015年 / 54卷 / 01期

关键词：

androgen; prostate; prostate cancer; androgen receptor; cancer initiation; CANCER-INSTITUTE BREAST; PLUS STANDARD CARE; PATHOLOGICAL STAGE; GENE FUSIONS; CELL-DIFFERENTIATION; TESTOSTERONE LEVEL; LUMINAL CELLS; GROWTH-FACTOR; RAT PROSTATE; MICE LACKING;

D O I：

10.1530/JME-14-0203

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Androgens and androgen receptor (AR) signaling are necessary for prostate development and homeostasis. AR signaling also drives the growth of nearly all prostate cancer cells. The role of androgens and AR signaling has been well characterized in metastatic prostate cancer, where it has been shown that prostate cancer cells are exquisitely adept at maintaining functional AR signaling to drive cancer growth. As androgens and AR signaling are so intimately involved in prostate development and the proliferation of advanced prostate cancer, it stands to reason that androgens and AR are also involved in prostate cancer initiation and the early stages of cancer growth, yet little is known of this process. In this review, we summarize the current state of knowledge concerning the role of androgens and AR signaling in prostate tissue, from development to metastatic, castration-resistant prostate cancer, and use that information to suggest potential roles for androgens and AR in prostate cancer initiation.

引用

页码：R15 / R29

页数：15

共 137 条

[1] Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer [J].

Agoulnik, Irina U. ;

Vaid, Ajula ;

Nakka, Manjula ;

Alvarado, Misty ;

Bingman, William E., III ;

Erdem, Halime ;

Frolov, Anna ;

Smith, Carolyn L. ;

Ayala, Gustavo E. ;

Ittmann, Michael M. ;

Weigel, Nancy L. .

CANCER RESEARCH, 2006, 66 (21) :10594-10602

[2] Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (reduce) trial [J].

Andriole, G ;

Bostwick, D ;

Brawley, O ;

Gomella, L ;

Tindall, D ;

Breed, S ;

Somerville, M ;

Rittmaster, R .

JOURNAL OF UROLOGY, 2004, 172 (04) :1314-1317

[3] ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients [J].

Baena, Esther ;

Shao, Zhen ;

Linn, Douglas E. ;

Glass, Kimberly ;

Hamblen, Melanie J. ;

Fujiwara, Yuko ;

Kim, Jonghwan ;

Minh Nguyen ;

Zhang, Xin ;

Godinho, Frank J. ;

Bronson, Roderick T. ;

Mucci, Lorelei A. ;

Loda, Massimo ;

Yuan, Guo-Cheng ;

Orkin, Stuart H. ;

Li, Zhe .

GENES & DEVELOPMENT, 2013, 27 (06) :683-698

[4] Androgen receptor as a target in androgen-independent prostate cancer - Discussion [J].

Sartor, O ;

Balk, SP ;

Brown, M .

UROLOGY, 2002, 60 (3A) :138-139

[5] Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice [J].

Banach-Petrosky, Whitney ;

Jessen, Walter J. ;

Ouyang, Xuesong ;

Gao, Hui ;

Rao, Jayashree ;

Quinn, John ;

Aronow, Bruce J. ;

Abate-Shen, Cory .

CANCER RESEARCH, 2007, 67 (19) :9089-9096

[6] Anti-inflammatory drugs, antioxidants, and prostate cancer prevention [J].

Bardia, Aditya ;

Platz, Elizabeth A. ;

Yegnasubramanian, Srinivasan ;

De Marzo, Angelo M. ;

Nelson, William G. .

CURRENT OPINION IN PHARMACOLOGY, 2009, 9 (04) :419-426

[7] WIDESPREAD DISTRIBUTION OF NUCLEAR ANDROGEN RECEPTORS IN THE BASAL-CELL LAYER OF THE NORMAL AND HYPERPLASTIC HUMAN PROSTATE [J].

BONKHOFF, H ;

REMBERGER, K .

VIRCHOWS ARCHIV A-PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY, 1993, 422 (01) :35-38

[8]

Bosland M C, 2000, J Natl Cancer Inst Monogr, P39

[9]

Bosland Maarten C, 2011, J Carcinog, V10, P33, DOI 10.4103/1477-3163.90678

[10]

Bubendorf L, 1999, CANCER RES, V59, P803

← 1 2 3 4 5 6 7 8 9 10 →